WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board of Directors. Mr. Rosenberg had a long and successful career at Novartis, most recently serving as Corporate Head of M&A and Licensing for all of Novartis. He previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales.
"It's very exciting to have someone of Tony's caliber joining our Board, including his years of expertise in strategic transactions and his deep and global knowledge in osteoporosis and oncology," said Kurt Graves, Chairman of the Board of Radius Health. "Our Board and management team are thrilled to have Tony become the newest member of the Board as we work together to guide and shape future success."
Tony Rosenberg will also be taking the role of Chair of the Strategy Committee, replacing Dr. Morana Jovan, who resigned from the Radius Board.
"The Board and I would like to thank Morana for the critical role she played in the transformation of Radius Health, and in helping to advance us to the stage where we are on the cusp of submitting abaloparatide for registration in the US and EU," said Robert E. Ward, President and CEO of Radius Health.
Tony Rosenberg first joined Sandoz in the UK in1980 where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994, he moved to Basel, initially in international product marketing, and after undertaking roles of increasing responsibility, he was named Head Global Marketing Primary Care. In 2000, Tony was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma). In this role, Tony managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions. In 2013, he was appointed as Corporate Head of M&A and Licensing. Most recently, Tony was responsible for the Portfolio Transformation transactions undertaken by Novartis. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan email@example.com (203)274-2825Source:Radius Health